Jinfeng pills ameliorate premature ovarian insufficiency induced by cyclophosphamide in rats and correlate to modulating IL-17A/IL-6 axis and MEK/ERK signals

• Published in: Journal of ethnopharmacology Vol. 307; p. 116242
• Main Authors: Hu, Ying-yi, Zhong, Rui-hua, Guo, Xiang-jie, Li, Guo-ting, Zhou, Jie-yun, Yang, Wen-jie, Ren, Bing-tao, Zhu, Yan
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 10.05.2023
• Subjects: Animals; Cyclooxygenase 2; Cyclophosphamide; Extracellular Signal-Regulated MAP Kinases; Female; Follicle Stimulating Hormone; Humans; IL-17/IL-6; Interleukin-17; Interleukin-6; Jinfeng pill; Matrix Metalloproteinase 3; MEK/ ERK; Menopause, Premature; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases - metabolism; Premature ovarian insufficiency; Primary Ovarian Insufficiency - chemically induced; Rats; Transcriptomics; IL-17/IL-6; Jinfeng pill; MEK/ ERK; Premature ovarian insufficiency; Transcriptomics
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2023.116242

Jinfeng Pill (JFP) is a classical Chinese medicine formula and composed of 9 herbs, including Epimedium brevicornu Maxim (Yinyanghuo), Cervus elaphus Linnaeus (Lurong), Panax ginseng C.A.Mey. (Renshen), Equus asinus (EJiao), Ligustrum lucidum W.T.Aiton (Nvzhenzi), Reynoutria multiflora (Thunb.) Moldenke (Heshouwu), Curculigo orchioides Gaertn (Xianmao), Neolitsea cassia (L.) Kosterm. (Rougui) and Leonurus japonicus Houtt. (Yimucao). The formula is clinically used to regulate menstrual cycle and alleviate polycystic ovarian syndrome due to its capabilities of ovulation induction. It is therefore presumed that JFP could be used for the therapy of premature ovarian insufficiency (POI) but the assumed efficacy has not been fully substantiated in experiment. To evaluate the effectiveness of JFP on cyclophosphamide (CTX)-induced POI and preliminarily explore its potential mechanisms of action. An experimental rat model of POI was established by using CTX induction to assess the efficacy of JFP. The potential targets of action for JFP alleviating POI were predicted by the combination of network pharmacology and transcriptomics and finally validating by RT-qPCR and Western blot. JFP alleviated the damages of ovarian tissue induced by CTX in the rat model of POI via significantly decreasing serum levels of FSH and LH and the ratio of FSH/LH and increasing the levels of E2 and AMH, accompanied with promoting ovarian folliculogenesis and follicle maturity and reversing the depletion of follicle pool. With the analysis of network pharmacology, pathways in cancer, proteoglycans in cancer, PI3K-AKT, TNF and FoxO signaling pathways were predicted to be influenced by JFP. The results of RNA-seq further revealed that IL-17 signaling pathway was the most important pathway regulated by both CTX and JFP, following by transcriptional misregulation in cancer and proteoglycans in cancer. Combining the two analytical methods, JFP likely targeted genes associated with immune regulation, including COX-2, HSP90AA1, FOS, MMP3 and MAPK11 and pathways, including IL-17,Th17 cell differentiation and TNF signaling pathway. Finally, JFP was validated to regulate the mRNA expression of FOS, FOSB, FOSL1, MMP3, MMP13 and COX-2 and decrease the release of IL-17A and the protein expression of IL-6 and suppress the phosphorylation of MEK1/2 and ERK1/2 in CTX induced POI rats. Jinfeng Pill is effective to ameliorate the symptoms of POI induced by CTX in the model of rats and its action is likely associated with suppressing IL-17A/IL-6 axis and the activity of MEK1/2-ERK1/2 signaling. [Display omitted] •Jinfeng Pill effectively ameliorates POI induced by cyclophosphamide in rats.•Jinfeng Pill balances sex hormone, promoting ovarian follicle growth and maturity.•Jinfeng Pill regulates ovarian immune response, especially IL-17 signaling pathway.•Jinfeng Pill suppresses IL-17A/IL-6 axis and MEK1/2-ERK1/2 signaling.